🇺🇸 Tetrathiomolybdate in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 10

Most-reported reactions

1. Anaemia — 1 report (10%)
2. Dyspnoea — 1 report (10%)
3. Headache — 1 report (10%)
4. Hepato-Lenticular Degeneration — 1 report (10%)
5. Leukopenia — 1 report (10%)
6. Liver Function Test Abnormal — 1 report (10%)
7. Malignant Neoplasm Progression — 1 report (10%)
8. Nausea — 1 report (10%)
9. Prescribed Underdose — 1 report (10%)
10. Pulmonary Embolism — 1 report (10%)

Source database →

Frequently asked questions

Is Tetrathiomolybdate approved in United States?

Tetrathiomolybdate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Tetrathiomolybdate in United States?

Dartmouth-Hitchcock Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.